Chi-Med and BeiGene start clinical cooperation
Hutchison China MediTech Limited (Chi-Med) today announced a clinical development cooperation agreement with BeiGene.
Hutchison China MediTech Limited (Chi-Med) today announced a clinical development cooperation agreement with BeiGene.
The two parties will carry out clinical trials in the United States, Europe, China and Australia to evaluate the safety, tolerability and efficacy of combined treatment of various solid tumors, of Chi-Med’s the candidate drugs sofatinib and fruquintinib, and BeiGene ’s anti-programmed death receptor 1 (PD-1 ) antibody Tislelizumab.
Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/27/chi-med-and-beigene-start-clinical-cooperation/.
